(UroToday.com) At the 2020 Virtual American Urological Association (AUA) annual meeting’s International Prostate Forum, Dr. James Gulley discussed implications of the genomic analysis for patients with metastatic castration-resistant prostate cancer (mCRPC) and why precision medicine for these patients matters. The role of genomic testing is to identify risk factors and prognostic factors (in healthy people or in cancer patients) and to identify potential treatment options for these cancer patients.